Fuat Oduncu

from Wikipedia, the free encyclopedia

Fuat Shamoun Oduncu (* 1970 in Midyat , Turkey ) is a German specialist physician for internal medicine , hematology , oncology and medical ethicist . He is Professor of Medicine at the Ludwig Maximilians University in Munich (LMU) and is known for his work in the fields of cancer research, palliative medicine , medical ethics and health economics .

biography

Fuat Shamoun Oduncu was born in Midyat (Southeast Anatolia / Turkey) and, as an Aramean (Mesopotamia), belongs to the Christian minority of the Syrian Orthodox Church . In 1974 his family emigrated as guest workers from Tur Abdin to Germany in the Bavarian town of Füssen . In 1989 he graduated from high school in Füssen and studied medicine at LMU Munich from 1989 to 1995. In 1997 he was awarded a doctorate at the Medical Faculty of the LMU Munich. med. PhD. At the same time, Oduncu studied philosophy at the University of Philosophy in Munich from 1992–96 , which he completed there with a Magister Artium (MA) and then in 2005 at the Philosophical Faculty of the LMU Munich as a Dr. phil. received his doctorate. In 1998 Oduncu received German citizenship (previously Turkish citizenship).

2000–2002 Oduncu completed a European postgraduate course European Master in Bioethics (EMB) at the universities of Nijmegen , Madrid , Leuven and Padua . In 2005 he completed his habilitation in internal medicine at the medical faculty of the LMU Munich. Oduncu began his career as a doctor in 1996 at the Medical Clinic and Polyclinic IV Clinic of the University of Munich . In 2004 he was recognized as an internist, in 2005 he was recognized for hematology and internal oncology. In 2006 he was appointed senior physician in hematology and oncology, and in 2007 head of hematology and oncology (successor to Bertold Emmerich). In 2008, Oduncu was granted the license to train to become a specialist in hematology and oncology. In 2009 he was recognized for the additional qualification in palliative medicine and in 2009 for haemostaseology . In 2009 he was granted the manufacturing license for autologous stem cells and he was appointed as an expert by the government of Upper Bavaria . In 2010 he was appointed chief medical quality management officer of the medical clinic and polyclinic.

From 2008 to 2011 Oduncu studied Master of Business Administration Health Care (MBA). at the Munich Business School in cooperation with the Boston University School of Management. In 2012 he was awarded the additional title of Medical Quality Management. In 2013 he was appointed professor at the LMU Munich.

As General Secretary of the Erich Frank Society, Oduncu works as a bridge builder for the relationships between the medical faculties of the LMU Munich and the University of Istanbul in the form of exchange programs ( Erasmus program ) for students and university teachers. As a member of the Board of Trustees of the Christian Development Service Foundation , Oduncu provides voluntary development aid in the poorest regions of India and Africa (construction of children's schools, poor houses).

Scientific contribution

In cooperation with other scientists (Georg Fey, Karl-Peter Hopfner) Oduncu is working on the development of so-called bi- and trispecific antibodies, the triple bodies. These are antibody derivatives that specifically recognize and eliminate cancer cells via their surface antigens . Using the principle of dual targeting (dual targeting), triple bodies can clearly identify, bind and destroy the cancer cell using two different surface features. This achieves a high level of effectiveness with very few side effects. In this way, this approach enables targeted, personalized cancer therapy and thus a realistic chance of long-term response and healing for each individual cancer patient. The Oduncu team first established the principle of triple bodies and dual targeting on the model of leukemia (blood cancer). Oduncu's work was supported by the renowned “m4 Award” for personalized medicine (top cluster funding from the BMBF and the Bavarian Ministry of Economics).

As medical ethicist Oduncu made numerous contributions on key issues of ethical and socio-political debates about dying with dignity, life care , euthanasia , euthanasia , palliative care , prioritization / Rationing / rationalization, organ transplantation , embryo and stem cell research .

Oduncu has written a total of more than 200 scientific contributions in the form of articles in specialist journals, books and conference papers.

Trivia

The theologian Andreas R. Batlogg dedicated his book Durchkreuzt - My life with the diagnosis of cancer (2019) a. a. Fuat Oduncu, "my lifesaver".

Publications

honors and awards

Memberships

  • German-Turkish Association for the Disabled, Munich
  • Academy for Ethics in Medicine (AEM), Göttingen
  • European Society for Philosophy of Medicine and Health Care (ESPMH)
  • German Society for Palliative Medicine
  • German Society for Hematology and Oncology (DGHO)
  • Munich Competence Center Ethics (MKE) of the LMU Munich
  • Board member of the European Society for the Philosophy of Medicine and Health Care (ESPMH)
  • Mentor of the Max Weber Program of the German National Academic Foundation
  • Member of the Board of Trustees of the Christian Development Service Foundation (CED)
  • German Cancer Society (DKG), Internal Oncology Working Group (AIO)
  • Secretary General of the Erich Frank Society for the Promotion of German-Turkish Relations between the Medical Faculties of the University of Munich and Istanbul

Web links

Individual evidence

  1. Erich Frank Society
  2. Christian Development Service
  3. Georg Fey ( Memento of the original from February 6, 2015 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice.  @1@ 2Template: Webachiv / IABot / www.mice.med.uni-erlangen.de
  4. ^ Karl-Peter Hopfner
  5. C. Kellner, J. Bruenke, J. Stieglmaier, M. Schwemmlein, M. Schwenkert, H. Singer, K. Mentz, M. Peipp, P. Lang, F. Oduncu, B. Stockmeyer, GH Fey: A Novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. In: Journal of Immunotherapy . 31 (9), 2008 Nov-Dec, pp. 871-884.
  6. H. Singer, C. Kellner, H. Lanig, M. Aigner, B. Stockmeyer, F. Oduncu, M. Schwemmlein, C. Stein, K. Mentz, A. Mackensen, GH Fey: Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. In: Journal of Immunotherapy. 33 (6), 2010 Jul-Aug, pp. 599-608.
  7. a b M. Kügler, C. Stein, C. Kellner, K. Mentz, D. Saul, M. Schwenkert, I. Schubert, H. Singer, F. Oduncu, B. Stockmeyer, A. Mackensen, GH Fey: A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. In: British Journal of Hematology 150 (5), 2010 Sep, pp. 574-586.
  8. ^ A b I. Schubert, C. Kellner, C. Stein, M. Kügler, M. Schwenkert, D. Saul, B. Stockmeyer, C. Beren, FS Oduncu, A. Mackensen, GH Fey: A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. In: mAbs. 4 (1), 2012 Jan-Feb, pp. 45-56.
  9. ^ A b I. Schubert, D. Saul, S. Nowecki, A. Mackensen, GH Fey, FS Oduncu: A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. In: MAbs. 2014 Jan-Feb 6 (1), pp. 286-296.
  10. a b T. A. Braciak, S. Wildenhain, CC Roskopf, IA Schubert, GH Fey, U. Jacob, KP Hopfner, FS Oduncu: NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triple body SPM-2. In: Journal of Translational Medicine . 11 (1), 2013 Nov 16, p. 289.
  11. ^ A b C. C. Roskopf, CB Schiller, TA Braciak, S. Kobold, I. Schubert, GH Fey, KP Hopfner, FS Oduncu: T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell. In: Oncotarget 5 (15), 2014, pp. 6466-6483.
  12. FS Oduncu: Personalized leukemia therapy through "dual targeting" with antibody derivatives (triple bodies). ( Memento of the original from February 6, 2015 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. m4 symposium. @1@ 2Template: Webachiv / IABot / www.m4.de
  13. ^ FS Oduncu: Die with dignity. Medical, ethical and legal aspects of euthanasia, terminal care and living wills. Vandenhoeck & Ruprecht Verlag, 2007.
  14. ^ FS Oduncu, S. Sahm: Doctor-cared dying instead of physician-assisted suicide: a perspective from Germany. In: Med Health Care Philos. 13 (4), 2010 Nov, pp. 371-381.
  15. G. Hohendorf, FS Oduncu: The medically assisted suicide: freedom to death or bondage to life? In: ZfmE. 57 (3), 2011, pp. 230-242.
  16. ^ FS Oduncu: Euthanasia: Killing as Due Care? In: Wiener Medical Wochenschrift. 153, 2003, pp. 387-391.
  17. FS Oduncu: Distributive justice, rationing and prioritization - the health system in the field of tension between medicine, economy, ethics and law. In: MedR. 30, 2012, pp. 359-367.
  18. FS Oduncu: Cost-benefit assessment within the framework of the drug market reorganization law (AMNOG) with special consideration of oncology. In: MedR. 30 (11), 2012, pp. 710-720.
  19. FS Oduncu: Priority-setting, rationing and cost-effectiveness in the German health care system. In: Med Health Care Philos. 16 (3), 2013, pp. 327–339 (JIF 1.303)
  20. FS Oduncu, U. Schroth, W. Vossenkuhl (Ed.): Transplantation. Organ extraction and allocation. In: FS Oduncu, U. Schroth, W. Vossenkuhl (Ed.): Medicine-Ethics-Law. Volume 2, Vandenhoeck & Ruprecht, Göttingen 2003.
  21. Fuat Oduncu: Brain Death and Organ Transplantation. Medical, legal and ethical issues. Vandenhoeck & Ruprecht, Göttingen 1998, ISBN 3-525-45822-3 .
  22. FS Oduncu, U. Schroth, W. Vossenkuhl (Ed.): Stem cell research and therapeutic cloning. In: FS Oduncu, U. Schroth, W. Vossenkuhl (Ed.): Medicine-Ethics-Law. Volume 1, Vandenhoeck & Ruprecht, Göttingen 2002.
  23. FS Oduncu, K. Platzer, W. Henn (Ed.): Access to the embryo. Ethical, legal and cross-cultural aspects of reproductive medicine. In: FS Oduncu, U. Schroth, W. Vossenkuhl (Ed.): Medicine-Ethics-Law. Volume 5, Vandenhoeck & Ruprecht, Göttingen 2005.
  24. AR Batlogg: Crossed - My Life with the Diagnosis of Cancer. Innsbruck 2019. p. 5.
  25. m4 Award Personalized Medicine ( Memento of the original from February 5, 2015 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice.  @1@ 2Template: Webachiv / IABot / www.m4.de
  26. For all awards see: Oduncu: Prizes, Honors ( Memento of the original dated February 5, 2015 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / www.klinikum.uni-muenchen.de